Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC.BCLI · Entity 7869 | Director · EVP & Chief Business Officer | February 26, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRAINSTORM CELL THERAPEUTICS INC.
Report date February 26, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 218,464 |
Reported balance
After 2026-02-26 transaction · row 1
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 150,000 · Balance 218,464 F1: Represents shares of restricted stock units ("RSUs") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of restricted stock units ("RSUs") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2026 Filed May 29, 2026 21:02 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-068338 · tm2615354-4_4seq1.xml · nonDerivative · entry 1 Yablonka Uri · CIK 0001608814 · Director · EVP & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,464 F1 · shares: Represents shares of restricted stock units ("RSUs") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 22:34 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-000892 · tm251864-7_4seq1.xml · nonDerivative · entry 2 Yablonka Uri · CIK 0001608814 · Director · EVP & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,464 F3 · shares: Represents shares of restricted stock units ("RSUs") awarded under the Plan. The RSUs shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. F2 · balance_after: Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 22:34 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-000892 · tm251864-7_4seq1.xml · nonDerivative · entry 1 Yablonka Uri · CIK 0001608814 · Director · EVP & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,464 F1 · shares: Represents shares of restricted stock awarded under the Issuer's 2014 Global Share Option Plan (the "Plan"). The shares of restricted stock shall vest as to (i) 50% of the award on the six-month anniversary of the date of grant and (ii) the remaining 50% of the award shall vest on the eighteenth-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. F2 · balance_after: Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024. Read SEC document |
| March 11, 2024 Filed Mar 14, 2024 00:56 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 109,426 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-034093 · tm248822-3_4seq1.xml · nonDerivative · entry 1 Yablonka Uri · CIK 0001608814 · Director · EVP & Chief Business Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,969 F1 · shares: The grant of restricted stock awards ("RSAs") to the Reporting Person as reported herein was approved by the board of directors of the Issuer on March 11, 2024 ("Grant Date") as part of the Issuer's grant of equity awards in the ordinary course. The RSAs shall vest in equal yearly installments over the course of two (2) years, with vesting occurring on each of the first and second anniversary of the Grant Date. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 22:01 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantStock Option (right to buy) · Derivative | 13,333 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001104659-21-151211 · tm2135659-2_4seq1.xml · derivative · entry 1 Yablonka Uri · CIK 0001608814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Underlying: Common Stock · 13,333 shares Expires 2031-12-15 F1 · derivative.exercise_date: Option vests and become exercisable in 12 consecutive, equal monthly installments commencing on January 15, 2022 until fully vested and exercisable on the 12 month anniversary of December 15, 2021. Read SEC document |
| December 10, 2021 Filed Dec 11, 2021 01:01 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantStock Option (right to buy) · Derivative | 13,333 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001104659-21-148747 · tm2135032-2_4.xml · derivative · entry 1 Yablonka Uri · CIK 0001608814 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Underlying: Common Stock · 13,333 shares Expires 2031-12-10 F1 · derivative.exercise_date: In connection with the Company's 2020 Annual Meeting of Stockholders, pursuant to the Company's Second Amended and Restated Director Compensation Plan, as amended, option vested and became exercisable in 12 consecutive, equal monthly installments commencing on December 11, 2020 until fully vested and exercisable on the 12 month anniversary of November 11, 2020, provided that the Reporting Person remained a member of the Board of Directors of the Issuer on each vesting date. Read SEC document |
| June 23, 2020 Filed Jun 26, 2020 21:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-077512 · tm2023245d1_4.xml · nonDerivative · entry 1 Yablonka Uri · CIK 0001608814 · Director · EVP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,543 Read SEC document |
| December 12, 2019 Filed Feb 14, 2020 22:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantStock Option (right to buy) · Derivative | 13,333 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001104659-20-021985 · tm205737d5_4.xml · derivative · entry 1 Yablonka Uri · CIK 0001608814 · Director · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Underlying: Common Stock · 13,333 shares Expires 2029-12-12 F1 · derivative.exercise_date: Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on January 12, 2020 until fully vested and exercisable on December 12, 2020, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
| November 30, 2018 Filed Nov 30, 2018 22:03 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantStock Option (right to buy) · Derivative | 13,333 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001144204-18-062651 · tv507902_4.xml · derivative · entry 1 Yablonka Uri · CIK 0001608814 · Director · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Underlying: Common Stock · 13,333 shares Expires 2028-11-30 F1 · derivative.exercise_date: Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on December 30, 2018 until fully vested and exercisable on November 30, 2019, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
| November 10, 2017 Filed Nov 13, 2017 21:37 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantStock Option (right to buy) · Derivative | 13,333 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001144204-17-058399 · tv479019_4.xml · derivative · entry 1 Yablonka Uri · CIK 0001608814 · Director · EVP and Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Underlying: Common Stock · 13,333 shares Expires 2027-11-10 F1 · derivative.exercise_date: Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on December 10, 2017 until fully vested and exercisable on November 10, 2018, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date. Read SEC document |
| August 23, 2017 Filed Aug 23, 2017 18:22 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | PurchaseCommon Stock | 2,000 | $3.98 | $7,960.00 |
DisclosureSEC source: 0001144204-17-044724 · v473922_4.xml · nonDerivative · entry 1 Yablonka Uri · CIK 0001608814 · Director · EVP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,543 Read SEC document |
| July 13, 2017 Filed Jul 17, 2017 21:00 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 5,543 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-037012 · v470768_4.xml · nonDerivative · entry 1 Yablonka Uri · CIK 0001608814 · Director · EVP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,543 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.